AbbVie: The Only Big Pharma Stock I'd Consider a Buy‑and‑Never‑Sell

There were times erstwhile investors whitethorn person disquieted astir hanging onto AbbVie (NYSE: ABBV) stock.

A decennary ago, much than 63% of the pharmaceutical giant's gross was tied up successful 1 cause -- Humira. Granted, it was the top-selling cause successful the satellite astatine the time. But contempt the 130 patents it received for Humira's assorted applications,  income were yet going to driblet erstwhile its patent extortion expired and it faced generic competition.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

Due to that competition, Humira's income fell from $21.2 cardinal successful 2023 to conscionable $4.5 cardinal successful 2025. But AbbVie's wide gross was amended than ever successful 2025, acknowledgment to the ascendance of 2 different immunology blockbusters: Skyrizi and Rinvoq. The company's quality to clasp disconnected generic competitors agelong capable to make a brace of replacement drugs for Humira that are much effectual successful the aforesaid indications was awesome -- and is 1 of the cardinal reasons wherefore I see AbbVie that uncommon buy-and-never-sell stock.

Here are 3 others.

AbbVie's shares are up a small much than 114% implicit the past 5 years, but the company's full instrumentality implicit that play is much than 160%. Counting its clip arsenic portion of Abbott Laboratories, AbbVie has accrued its dividend for 54 consecutive years, including a 5.5% bump this year. That makes it a Dividend King, 1 of the uncommon companies with payout-hiking streaks of 50 years oregon more. Since its spinoff from Abbott successful 2013, AbbVie has raised its payouts by much than 330%.

At its existent stock price, the banal yields astir 2.8%, much than doubly the mean output of the S&P 500. It's uncommon for a institution with this overmuch maturation to besides person that overmuch worth arsenic an income-producing stock.

In 2025, the institution had 10 therapies with yearly income of $1 cardinal oregon more. That didn't hap by accident. AbbVie has spent large connected acquisitions to physique up its pipeline, and continues to bash so.

It conscionable plunked down $650 cardinal successful January for 1 promising oncology drug, RC148, developed by Chinese pharmaceutical institution RemeGen. It's a next-generation bispecific therapy designed to dainty assorted precocious coagulated tumors. A bispecific therapy tin hindrance to 2 chiseled targets simultaneously, acting arsenic a span betwixt a crab compartment and an immune cell.